Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Tom said patients who remain ctDNA-positive after surgery, roughly 18 weeks out, have a median PFS of only about four months and do very poorly regardless of prior therapy. John Chatzko called this an unmet need and pointed to an upcoming adjuvant DATO-DXD trial as a possible option.

Related Insights

The prognostic value of a positive ctDNA test in urothelial cancer intensifies throughout the treatment journey. Failure to clear ctDNA after neoadjuvant therapy and then surgery is associated with a dramatically increasing hazard ratio for death, signaling profound treatment failure.

While trials like IMvigor011 show ctDNA can guide adjuvant immunotherapy after surgery, this data may not apply to the new standard of care. With neoadjuvant EV/pembrolizumab becoming prevalent, the prognostic and predictive value of post-operative ctDNA is now unknown, requiring new prospective studies.

Tom noted post-surgery ctDNA positivity fell to 5% on EV+Pembro versus 15% on chemotherapy, and the chemo arm also declined. He suspects surgery accounts for only part of the drop, with delayed immune clearance from EV+Pembro contributing; the durability of response evolves over months. So the surgical effect is not the whole story.

In patients under surveillance for colorectal cancer, the median time from a positive ctDNA test to radiographic recurrence is extremely short—only 3 to 5 months. This narrow window underscores the high-risk nature of this state and the critical urgency required to enroll these patients into clinical trials immediately upon ctDNA detection.

In early-stage non-small cell lung cancer, the presence of circulating tumor DNA before surgery is not a statistically significant predictor of survival. However, detecting ctDNA after curative-intent surgery is a strong negative prognostic indicator, highlighting the critical value of post-operative testing.

Emerging data from major trials shows that ctDNA clearance during neoadjuvant therapy and negative post-surgical MRD status are strong predictors of improved survival. MRD positivity, in contrast, is associated with worse biology and rapid progression.

In neoadjuvant therapy, a patient's long-term outcome is better predicted by stopping tumor DNA shedding (ctDNA clearance) than by achieving pathologic complete response (pCR), the traditional gold standard. This redefines what constitutes a successful treatment response before surgery.

While adjuvant immunotherapy benefits ctDNA-positive patients, it may not be the optimal strategy. Given their near-certainty of relapse (95%), using a single-agent immunotherapy when a more potent combination like EV-Pembro exists for metastatic disease raises the critical question of whether these high-risk patients are being undertreated.

The interpretation of ctDNA is context-dependent. Unlike in the adjuvant setting, in the neoadjuvant setting, remaining ctDNA positive post-treatment signifies that the current therapy has failed. These high-risk patients need a different therapeutic approach, not an extension of the ineffective one.

A positive ctDNA (MRD) test after surgery is seen as a stronger predictor of recurrence than traditional histopathological features. This result pushes clinicians to recommend more aggressive adjuvant chemotherapy, such as extending the duration to a full six months, and to increase the frequency of surveillance imaging.